What this risk is, and why it matters
Regulatory approval risk is the exposure that a transaction needs sign-off from antitrust, foreign-investment or sector regulators, and that one of them blocks, delays or reshapes it. For a senior executive, the concern is certainty and timing: a deal contingent on clearance carries the risk of a long conditionality period, mandated divestments that undermine the deal logic, or an outright prohibition that wastes months of effort and exposes the buyer to break fees.
Legal and regulatory framework
This risk sits squarely within named regimes: merger control under authorities such as the European Commission, the UK CMA, the US agencies under Hart-Scott-Rodino, and equivalents elsewhere; foreign-investment screening such as CFIUS in the US and the UK National Security and Investment Act; plus sector regulators in finance, telecoms, defence and utilities. Enforcement has become more assertive on both competition and national-security grounds, lengthening reviews and widening the deals that are caught.
Typical scenarios and impact
Scenarios span quick unconditional clearance, conditional approval requiring behavioural commitments or divestments, extended Phase 2 investigations, and prohibition. Remedies can strip out a meaningful share of the target's value, while delay raises financing and integration costs. Break fees and reverse break fees, often a defined percentage of deal value, crystallise when approvals fail. For sensitive sectors, a refused foreign-investment clearance can end a deal outright and attract public scrutiny.
Mitigation framework and when to engage an expert
Map every required clearance early, assess substantive theories of harm, and build realistic timing and conditionality into the contract through clear conditions, long-stop dates and well-calibrated break fees. Prepare filings and remedy proposals proactively. Engage antitrust and regulatory counsel at the outset, and foreign-investment specialists where national-security review is plausible. The goal is to price and allocate approval risk before signing, not to discover it during a stalled review.